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Complex interactions among cells of the
monocyte-macrophage-osteoclast lineage and the
mesenchymal stem cell-osteoblast lineage play a major
role in the pathophysiology of bone healing. Whereas
the former lineage directs inflammatory events and
bone resorption, the latter represents a source of cells
for bone regeneration and immune modulation. Both
of these lineages are affected by increasing age, which
is associated with higher baseline levels of inflammatory
mediators, and a significant reduction in osteogenic
capabilities. Given the above, fracture healing,
osteoporosis, and other related events in the elderly
present numerous challenges, which potentially could
be aided by new therapeutic approaches to modulate
both inflammation and bone regeneration.when the CCR2-monocyte chemotactic protein-1Background
Most developed countries are facing an aging popula-
tion. Currently, persons over 65 years of age represent
13 % of the American population [1], and this number is
expected to grow as the “Baby Boomer” generation con-
tinues to age beyond 65 [2]. By 2030, they are projected
to represent 16.9 % of the population; this segment will
increase to 25.8 % by 2060 [3]. The changing demo-
graphics of the world’s population have wide-ranging
implications that include a shift in medical needs.
Bone fractures are among the most common orthopedic
problems that require medical intervention, particularly in
the elderly. Almost half of fractures are related to osteo-
porosis, especially in individuals over the age of 55 [4].
Beyond the impact on the health and quality of life of indi-
vidual patients, fractures are expensive and present a
multi-billion-dollar cost to society because of direct and
indirect costs [4]. With an increasingly aging population, a* Correspondence: goodbone@stanford.edu
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is critical in developing and optimizing effective thera-
peutic treatments.
Bone healing is a complex process. After bone injury,
a stage of inflammation is necessary for progression to
healing. In vivo studies have shown early secretion of
pro-inflammatory factors such as interleukin (IL)-1 and
IL-6, tumor necrosis factor-alpha (TNFα), macrophage
colony-stimulating factor (M-CSF), and inducible nitric
oxide synthase (iNOS) [5]. In a study of double TNFα
gene knockout mice (p55−/−/p75−/−), Gerstenfeld et al.
[6] showed that pro-inflammatory signals are required
for proper bone repair, as these mice failed to initiate
intramembranous bone formation and had markedly re-
duced expression of type 1 collagen and osteocalcin
mRNA. Moreover, Xing et al. [7], using CCR2−/− mice,
have shown that inflammation is critical to bone healing;
(CCR2-MCP-1) chemokine-receptor axis was interfered
with, inflammation and bone healing were impaired.
Bone marrow macrophages (also called osteal macro-
phages) are also important for the repair of bone by coord-
inating the crosstalk between osteoclasts and osteoblasts
[8]. Furthermore, using the macrophage Fas-induced apop-
tosis (MAFIA) transgenic model, Cho et al. [9] showed that
osteal macrophages mediated parathyroid hormone-
dependent bone regeneration. Other studies also reported
the important role of osteal macrophages in the processes
of bone healing [10–12].
Beyond pro-inflammatory signals, macrophages also
secrete many growth factors and chemokines that are
critical during the inflammatory phase of bone heal-
ing [6, 13]. These growth factors include transforming
growth factor-beta (TGFβ), insulin-like growth factor
(IGF), fibroblast growth factor (FGF), and platelet-derived
growth factor (PDGF). Macrophages also secrete chemo-
kines, such as MCP-1 and monocyte inflammatory protein
1 alpha (MIP-1α), that are essential for mesenchymal stem
cell (MSC) homing and migration to the injured site [14].is distributed under the terms of the Creative Commons Attribution 4.0
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regeneration. MSCs are multipotent and can differenti-
ate into many cell types, including chondrocytes and
osteoblasts for endochondral and intramembranous ossi-
fication, respectively [14]. A key step in bone healing is
the localization of MSCs to the site of injury. For ex-
ample, in a parabiosis model, Shinoara et al. [15] demon-
strated that the stromal cell-derived factor 1/CXCR4
(SDF-1/CXCR4) ligand-receptor axis is critical for the
homing of progenitor cells that participate in fracture
healing. Similarly, Kitaori et al. [16] used an exchanging-
graft and autograft mouse model to show that SDF-1+/−
and CXCR4+/− are important to the recruitment of
MSCs during skeletal repair. Many other studies have
confirmed the beneficial role of MSCs in bone regener-
ation [17, 18]. Nevertheless, the origin of the MSCs that
are directly involved in fracture healing is controversial.
Colnot et al. [19] showed that periosteum and endos-
teum are primary sources of MSCs for fracture repair.
Similarly, using a parabiotic mouse model, Kumagai
et al. [20] showed little to no contribution of circulating
cells to direct repair of the injured bone. At a minimum,
systemically migrated MSCs and osteoprogenitors are
thought to play an important paracrine role, modulating
both inflammation and subsequent bone repair.
Given the above, there appears to be a deficiency in
our understanding of the interactions between macro-
phages and MSCs in bone healing, especially in the
elderly population. Specifically, aging may alter these
interactions and thereby play an important role in the
elderly patient’s ability for regeneration of musculoskel-
etal tissues. This review will address the effect of agingFig. 1 The effect of aging on mesenchymal stem cells and macrophages. ↑ in
colony-stimulating factor, MΦ macrophage, MSC mesenchymal stem cell, SA-β
TNF-α tumor necrosis factor-alphaon both macrophages and MSCs as it relates to bone
healing. Figure 1 summarizes the effect of aging on
MSCs and macrophages.
The concept of macrophage polarization
Bone injury leads to the production of pro-inflammatory
cytokines and chemokines and to systemic recruitment of
macrophage precursors to the injury site [21]. As such, it is
important to understand the different macrophage popula-
tions that play a role in bone repair. Though they exist
within a spectrum, macrophages can be broadly described
as uncommitted M0, pro-inflammatory M1, and anti-
inflammatory M2 populations [22]. Mantovani et al. [23]
have shown that these designations are similar in humans
and mice. M0 macrophages can be polarized to pro-
inflammatory M1 macrophages by interferon-gamma
(IFNγ) and lipopolysaccharide (LPS) via Toll-like receptors
(TLRs) like TLR-4, whereas both M0 and M1 macro-
phages can be polarized to an anti-inflammatory M2
phenotype by exposure to IL-4 [24, 25]. M1 macrophages
are characterized by a cytokine release profile of TNFα,
IL-6, IL-1, IL-12, IL-23, Oncostatin M (OSM), and type 1
IFN with increased expression of iNOS, CCR7, and HLA-
DR [26, 27]. Alternatively, the M2 cytokine release profile
includes IL-4, IL-10, IL-13, and IL-1ra and increased
expression of CD206, Ym1 (eosinophil chemotactic
factor), CD163, CCL1, CCL18, FIZZ1, Arginase 1, and
chitotriosidase [28, 29]. In actuality, both in humans and
mice, there probably exists a spectrum of polarization
phenotypes, with a general preponderance of pro- versus
anti-inflammatory properties. With these multiple pheno-
types, macrophages play several roles within the bone-crease, ↓ decrease, BM bone marrow, GM-CSF granulocyte macrophage
-gal senescence-associated β-galactosidase, TLR4 Toll-like receptor 4,
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and environmental cues. For instance, in humans, re-
trieved periprosthetic tissues revised because of loosening
and osteolysis demonstrated increased M1/M2 macro-
phage ratios [25].
Aging and macrophages
Macrophages are essential components of the innate and
adaptive immune systems, in the maintenance of physio-
logical homeostasis, and in bone remodeling [11]. As
these cells play an important role in a wide variety of
processes, a clear knowledge of how macrophages func-
tion and how they change with age is crucial for under-
standing both healthy and pathological states.
Intrinsic changes with aging
Although it is apparent that macrophages have altered
activities with age, it is unclear as to what these specific
changes entail and the mechanisms that drive such
changes in musculoskeletal tissues. Several studies point
to intrinsic factors that alter macrophage polarization,
function, and survival. Wang et al. [30] found that aged
murine muscle had higher levels of M2a polarized mac-
rophages, muscle fibrosis, and collagen accumulation.
The increased frequency of M2a macrophages and fibro-
sis was attributable to the aging of myeloid lineage cells,
as demonstrated by rescue of aged muscle with infusion
of young bone marrow cells [30]. Interestingly, inducing
muscle-specific neuronal nitric oxide synthase (nNOS)
was sufficient to prevent increased M2a frequency
and arginase-1-dependent fibrosis [30]. Shortening of
telomeres in aged macrophages also contributes to
macrophage susceptibility to oxidative stress and
reduced granulocyte macrophage colony-stimulating
factor (GM-CSF)-dependent proliferation [31]. These cel-
lular defects were found in aged and telomerase knockout
(Terc−/−) mice; Sebastian et al. concluded that telomere
loss caused reduced STAT5a oxidation and phosphoryl-
ation and ultimately impairment of GM-CSF-dependent
macrophage proliferation [31]. Similarly, increased levels
of S-endoglin, a transmembrane glycoprotein associated
with inflammatory processes, were associated with
decreased macrophage proliferation, decreased survival
response to GM-CSF, increased oxidative stress, and
skewed myeloid cell polarization toward an M2 phenotype
[32]. Chitotrioside, a marker for chronically activated mac-
rophages and inflammation, has also been shown to be el-
evated in older humans [33]. Herrero et al. demonstrated
that, at the genomic level, aged macrophages have
decreased DNA-binding activity in the promoter region of
the IAβ gene, resulting in decreased expression of major
histocompatibility complex (MHC) class II molecules [34].
As evidenced by the changes described above, aging alters
many aspects of macrophage survival and function.Aging microenvironment
In addition to intrinsic changes of aging, macrophages
are modulated by their aging microenvironment and a
poorly described number of external factors. When
challenging young macrophages with aged serum,
Gomez et al. found reduced macrophage secretion of
TNFα and increased basal levels of IL-6 [35]. Though
the group did not specifically identify the factors con-
tributing to these observations, they concluded that,
owing to heat resistance of the effect, the stimulatory
factor(s) for increased IL-6 production was not a protein
[35]. In a study comparing phagocytosis by young and
aged peritoneal macrophages and bone marrow-derived
macrophages (BMDMs), Linehan et al. demonstrated that
older peritoneal macrophages have significantly impaired
phagocytosis compared with younger macrophages; how-
ever, there was no evident defect in phagocytosis for aged
BMDM [36]. Moreover, they found that injection of young
peritoneal macrophages into the peritoneal cavities of
aged mice led to impaired phagocytosis and increased
levels of T and B cells [36]. Barrett et al. found that glial
cells exposed to conditioned media from aged BMDMs
challenged with IFNγ or LPS had increased expression of
pro-inflammatory mediators [37]. Such a pro-inflammatory
environment could further mediate increased inflamma-
tion by infiltrating macrophages and thus contribute to a
cascade of cellular damage [37]. Together, these findings
suggest a profound influence of the aging microenviron-
ment on macrophage function.
Inflamm-aging
Aging is also associated with elevated levels of secreted
inflammatory cytokines beyond the previously described
functional and environmental changes [38]. Much of the
literature describes aged macrophage hypersensitivity
and increased responsiveness to inflammatory signals.
For example, when aged BMDMs are challenged with
IFNγ or LPS, they increase their expression of arginase
and secrete characteristic pro-inflammatory M1 and
Th1 cytokines, such as TNFα, NOS2, IL-1β, and IFNγ
[30, 37, 39]. Moreover, aged macrophages increase
their surface density of TLR4, the receptor for LPS,
permitting a faster and enhanced inflammatory re-
sponse [40]. Similarly, Smallwood et al. found that
aged macrophages have increased nitric oxide produc-
tion under resting conditions as well as enhanced
bactericidal activity against Salmonella [41]. These
findings suggest that aged macrophages remain in a
pre-activated resting state that enhances their re-
sponse to exposure of pro-inflammatory stimuli [41].
However, with increased production of reactive oxygen
species, aged macrophages are susceptible to oxidative
damage [41]. Although there is increased responsiveness
to pro-inflammatory signals, aged macrophages also have
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duced nitrite burst capacity, and reduced autophagy [38].
Recently, the phenomenon of “inflamm-aging” has
been challenged by several studies that have shown
decreased macrophage responsiveness to inflammatory
signals. Some studies have shown that aged macrophages
are less responsive to IFNγ and LPS as evident by de-
creased macrophage-mediated tumoricidal activity and
reduced secretion of TNFα, IL-1β, IL-6, iNOS, and IFNγ
[42–44]. Though the mechanisms for these changes are
still unclear, it has been shown that age-associated
decrease in IFNγ responsiveness is at least partially me-
diated by the lack of tyrosine phosphorylation of
mitogen-activated protein kinase (MAPK) [45]. Similarly,
aged mice highly express miR-146a, a microRNA that
negatively regulates IL-1β and IL-6 via LPS and the nu-
clear factor kappa-light-chain-enhancer of activated B cells
(NFκB) pathways [43]. These differing findings suggest
that aged macrophages can be modulated under various
conditions and are likely part of a more dynamic interplay
among intrinsic aging mechanisms, the microenviron-
ment, and different populations of surrounding cells.
Broader implications
Given current knowledge, it is apparent that aging-
associated changes in the macrophage population are
normal events but can also be potential sources for
pathological states. As such, modulation of macrophages
can provide an avenue for future therapeutics. For ex-
ample, Slade Shantz et al. demonstrated that blocking
macrophage activity by using PLX3397, a drug that
blocks the kinase domain of CSF-1R, can accelerate
bone callus maturation and subsequent bone formation,
illustrating a potential means of enhancing fracture heal-
ing and preventing nonunion in the elderly [46]. Several
studies showed that aging affects fracture healing in ani-
mal models. Histing et al. [47] compared fracture healing
in both young and aged senescence-accelerated mice
(SAMP6) and senescence-resistance mice (SAMR1).
Fracture healing was delayed in aged SAMP6 mice com-
pared with aged SAMR1 mice. The authors concluded
that increased osteoclast activity in aged SAMP6 mice
was responsible for the difference. However, Egermann
et al. [48], using the same model, did not find any differ-
ences. Interestingly, using a chimeric model, Xing et al.
[49] showed that aged mice receiving juvenile bone mar-
row cells could accelerate their age-related delay in frac-
ture healing. A decrease in cyclooxygenase 2 (COX-2)
expression in the early inflammatory phase of bone re-
pair resulting in delayed remodeling in aged mice was
observed by Naik et al. [50]. Lu et al. [51] found a de-
creased number of chondrocytes expressing collagen II
and osteoblasts expressing osteocalcin in middle-aged
and elderly mice, compared with younger mice.With regard to therapy, in order to target age-related
inflammation, clinicians have used estrogen to treat a
variety of inflammation-mediated conditions, including
traumatic injuries [52]. With a better understanding of
how macrophages change with age and mediate different
disease states, new therapeutics that specifically target
these aspects of macrophage function can be developed.Aging and mesenchymal stem cells
The use of MSCs and MSC-derived osteoprogenitors in
orthopedic surgery is gaining more widespread acceptance.
Hernigou et al. pioneered the use of MSC-derived osteo-
progenitors to treat osteonecrosis of the hip and other
conditions involving bone healing [53]. A recent study ex-
tended the use of harvested osteoprogenitors to treat sec-
ondary osteonecrosis of the knee with promising results
[54]. However, the management and use of MSCs are nu-
anced, and Prockop [55] has shown that the microenviron-
ment into which MSCs are injected is critical and involves
inter-cellular communication via soluble factors and com-
plex cellular interactions. The effect of aging on MSCs is
highly relevant, as cell-based therapies for both regener-
ation and immune modulation are developing rapidly.Abundance and growth
As the skeleton ages, the quantity of MSCs in the bone
marrow decreases. Quarto et al. [56] compared the num-
ber of bone progenitor cells in adult and aged rats and
found a significantly decreased number of bone progeni-
tors in the bone marrow with aging. However, Chen [57]
observed that the total number of MSCs harvested from
mice was significantly higher in older mice (by approxi-
mately 20 %), but the older mice failed to produce as
many osteoprogenitor cells compared with younger
mice. Using specimens harvested from the iliac crest in
healthy patients aged 5 to 70 years, Shigeno and Ashton
[58] showed a significant decrease in both the number
of precursor cells and degree of proliferation starting in
the second and third decades of life. Likewise, Muschler
et al. [59] investigated the dependence of nucleated cell
and osteoblastic progenitor numbers in bone marrow as-
pirates on the basis of the age and gender of the patient.
Expectedly, the total number of nucleated cells de-
creased with age regardless of gender, but surprisingly
the number of osteoblastic progenitors did not decrease
significantly for men whereas it did for women. More-
over, Stolzing et al. [60] also found a decrease in the
number and proliferative capacity of MSCs harvested in
older humans. Taken together, these data indicate that
aging decreases the availability and growth potential of
MSCs for bone formation. Furthermore, these changes
may be dependent on the sex of the host.
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The potential for differentiation of MSCs according to
age is controversial, but most of the studies have shown
a decrease in their capacity to undergo osteogenic differ-
entiation. Baxter et al. [61] harvested human MSCs
(hMSCs) from donors aged 0 to 18 (hMSCs0-18) and 59
to 75 (hMSCs59–75). The proliferative capacity and num-
ber of colony-forming-unit alkaline phosphatase-positive
(CFU-ALP+) cells were decreased in hMSCs59–75. The
authors also measured the mean telomere restriction
fragment (mTRF), which can be used to estimate the
remaining replicative capacity of a cell population. They
found that mTRF in hMSCs0–18 was significantly longer
than in hMSCs59–75. In another study, Zhou et al. [62]
reported on cultured hMSCs from donors aged 17 to 90.
Aged hMSCs showed increased numbers of senescence-
associated β-galactosidase (SA-β-gal)-positive cells, ap-
optotic cells, a decreased proliferation rate, and ALP+
cells. Aged hMSCs also experienced genetic flaws with
overexpression of p53 and its target p21 and BAX
(apoptosis regulator) genes (apoptotic pathway). Kuehn
[63] also reported major genetic flaws such as chromo-
somal rearrangement or overexpression of the MYC
oncogene. Similarly, D’Ippolito et al. [64] found signifi-
cantly fewer CFU-ALP+ cells in cultured MSCs from
vertebral bone marrow from older donors. A potential ex-
planation of the failure of aged MSCs to differentiate may
be due to shortening of telomere length. To test this hy-
pothesis, Liu et al. compared telomerase knockout MSCs
(mTR−/−MSCs) to wild-type MSCs (WT-MSCs) [65]. Their
results showed a complete failure of mTR−/−MSCs to
differentiate into chondrocytes. Moreover, mTR−/−MSCs
experienced early morphologic alterations. Pignolo et al.
[66] also validated this hypothesis by using a mouse model
of Werner syndrome (premature aging). The role of cell
cycle regulators has been shown to be critical for the
regulation of cellular senescence. Among the cell cycle reg-
ulators, p16INK4A, which interferes with CDK4 and CDK6
cell cycle kinases, was found to be overexpressed in aged
hMSCs [67].
Wound healing is also affected by senescence.
Choudhery et al. [68], in an in vitro study, showed
decreased wound-healing abilities with murine MSCs
(mMSCs) harvested from aged mice. Interestingly, they
also found a downregulation of vascular endothelial
growth factor (VEGF), stromal cell-derived factor 1 che-
mokine (SDF-1), and protein kinase B (which is known
to inhibit apoptosis) expression in aged mMSCs. Angio-
genic potential was also dramatically decreased in aged
mMSCs. The potential for regeneration of muscle by
MSCs is also profoundly affected by senescence. Resident
muscle MSCs, also known as satellite cells, lose their self-
renewal abilities via alterations in FGF receptor 1 and
p38αβMAPK signaling, as shown by Bernet et al. [69].Conclusions
With aging, the proliferative and functional abilities of
macrophages and MSCs are impaired because of a
combination of intrinsic and environmental factors. As
proper bone healing requires an inflammatory phase, the
increased survival of anti-inflammatory M2 macrophages
and reduced secretion of pro-inflammatory factors with
age may jeopardize timely bone regeneration. At the
same time, aging negatively impacts MSC proliferation
and differentiation, further impeding the bone-healing
process. It would appear that, taken together, both mac-
rophages and MSCs, cells critical for regeneration of
musculoskeletal tissues, are adversely affected by aging.
This scenario provides new opportunities for modulation
of cellular events in order to optimize the healing of
mesenchymally derived tissues, including bone.Abbreviations
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